Wells Fargo Turns Bullish on Alector, Citing Overlooked Brain Delivery Technology
Wells Fargo initiates Alector with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137.
Already have an account? Sign in.